PRM-151 therapy well tolerated by patients with advanced myelofibrosis

PRM-151 therapy well tolerated by patients with advanced myelofibrosis
PRM-151 therapy well tolerated by patients with advanced myelofibrosis

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.

The study showed the compound was well tolerated in the 27 patients observed. It was led by Srdan Verstovsek, MD, PhD, professor of leukemia at The University of Texas MD Anderson Cancer Center in Houston, and it was presented at the 56th annual meeting of the American Society of Hematology in San Francisco, California.

"There was no evidence of drug-related myelosuppression or suppression of the bone marrow's ability to produce blood cells and platelets. We also saw encouraging trends in both clinical and histologic aspects of the disease," said Verstovsek. "With demonstrated reduction in bone marrow fibrosis, stable to improved hematologic parameters, symptom responses, and stable to reduced spleen size, it is clear that there is merit for further development of PRM.

Myelofibrosis is caused by the accumulation of malignant bone marrow cells that triggers an inflammatory response, scarring the bone marrow and limiting its ability to produce blood, resulting in anemia. About 3,000 new cases of myelofibrosis are diagnosed in the United States each year. Average survival ranges from 2 to 11 years, depending on a variety of prognostic factors.

Patients with myelofibrosis experience many debilitating symptoms including fatigue, weight loss, abdominal pain, severe itching, night sweats, and bone pain. A swollen spleen is one hallmark of the disease tied to many of its symptoms.

PRM is a recombinant form of Pentraxin-2, a human protein that acts at sites of tissue damage, inducing macrophage differentiation to prevent and reverse fibrosis. PRM has demonstrated broad antifibrotic activity in multiple preclinical models of established fibrotic diseases and no dose-limiting toxicities in phase I trials. Verstovsek found that PRM was well tolerated both in combination with, and without ruxolitinib, another potent myelofibrosis therapy.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs